Slava Akmaev is the Chief Technology Officer at Scipher Medicine. He is responsible for product development in precision medicine and early discovery efforts in drug development using the Network Medicine platform. He has been recognized as a leader in the adoption of the AI/ML technology in healthcare and drug development and is a frequent speaker at some of the most prolific industry events. Slava is the inventor on a number of issued and pending patent applications and has published more than 30 peer-reviewed articles in computational biology, artificial intelligence and molecular biology. Additionally, he authored book chapters and numerous scientific presentations and posters.
Lori Anderson is product marketing manager for precision medicine informatics at XIFIN, where she brings many years of experience in medical affairs and product portfolio management in the healthcare and life-sciences industries. Prior to joining XIFIN, Lori was the director of health economics and outcomes research at Quest Diagnostics where she defined the reimbursement strategy for numerous tests routinely used in precision medicine. As a laboratorian herself with a particular interest in hematological neoplasms and the role of platelets in cardiovascular disease, Lori has contributed to the publication of 10 book chapters, 20 peer reviewed publications and over 40 poster presentations and has presented on numerous topics in laboratory medicine and life sciences worldwide.
Heather is a passionate professional that has worked within diagnostic medical imaging startups for over 15 years. Applying her software development and program management skills, she led a disciplined effort to earn a positive BCBS Evidence Street review, CMS New Technology APC payment classifications, Category III codes, and greater than 90% commercial coverage in 18 months for HeartFlow’s core technology, FFRct. Today, her leads her team to push the envelope on alternative payment models and value-based discussions with payers. Heather earned her Ph.D. in Biomedical Engineering from Vanderbilt University with a focus in neuroelectrophysiology.
An experienced healthcare executive with a proven track record of innovative value based reimbursement strategies, Lena Chaihorsky has spent her career studying reimbursement and the managed care industry from the perspective of diagnostics. With a background in biology and mathematics from Tufts, she has held leadership positions in sales, national contracting, and reimbursement for both start up and global diagnostics companies prior to co-Founding Alva10. Her thought leadership in payment innovation recently led to appointment on World Economic Forum working groups on Precision Medicine.
Dana is an accomplished and enthusiastic marketing professional with decades of experience in corporate marketing and publishing, membership, and partner/project management. After 25 years at National Geographic, she is now in a new career in the health and wellness arena at Inspire, the leading social network for health, who’s mission is to accelerate medical progress through a world of connected patients.
Tony Grover brings over 20 years of experience and expertise in business development, strategic partnerships, licensing, reimbursement and new technology platform development as an executive in the diagnostic and medical device industries. Tony has raised over $100M in cumulated capital, negotiated a variety of deals including licenses, strategic investment, joint ventures, and lab service agreements.
Patricia Goede is VP Clinical Informatics at XIFIN, Inc., where she brings 22 years’ experience developing biomedical imaging informatics solutions and technology to facilitate multi-modality and multispecialty image-based exchange, collaboration, and management in distributed environments. Goede founded VisualShare and served as CEO until its acquisition by XIFIN in 2015. Previously, Goede was at the University of Utah where she pioneered a number of image, visualization and collaboration tools. She is the founder of the Electronic Medical Education Resource Group (EMERG), and as its director, established the Utah Center of Excellence for Electronic Medical Education. Goede holds an MS in Computational Visualization and a PhD. in Biomedical Imaging Informatics.
Mark Hiatt, currently Vice President for a precision oncology company, has served as the Chief Medical Executive for a multi-state Blues plan and a National Medical Benefits Manager, and Department Leader and Board Member for a regional health system. Dr. Hiatt completed a fellowship in cardiovascular imaging at Stanford University, residency in radiology and master’s in Health Evaluation Sciences at the University of Virginia, and MD and MBA with academic distinction at Wake Forest University. He is the Chair of the Greater Salt Lake Chapter of the American Red Cross.
Dr. Hurban is Senior Director and Global Head of Translational Genomics at Q2 Solutions. In this role, he is responsible for the identification and implementation of new genomic capabilities, encompassing bioinformatics and wet-laboratory methods, as well as the development and validation of genomic assays to support research and clinical programs. These include broad-based screening assays, such as exome and RNA sequencing, to highly focused expression, genotyping and sequencing assay panels that target a smaller number of genes. Dr. Hurban has more than 25 years of experience in molecular genetics, including more than 18 years in positions of increasing responsibility in high-profile genomics-focused organizations. His research interests have focused on the genetic control of gene expression and have spanned diverse fields such as toxicology, developmental, and cancer biology.
Christiana Iyasere, MD, MBA, is a graduate of Yale College and Columbia University, College of Physicians and Surgeons. She completed her residency at Mass General in internal medicine in 2005. Following her tenure as a medical resident at Mass General, Dr. Iyasere undertook an administrative fellowship under the guidance of Dr. Peter Slavin, with an emphasis on technology evaluation, adoption and promotion. She subsequently went to Harvard Business School for continued management training and finished her degree in 2008. Since that 2008 Dr. Iyasere has been involved in the development of enterprise wide technology accelerators both for Partners Healthcare and Massachusetts General Hospital. She currently is the Director of the MGH Department of Medicine Innovation Program and is responsible for a portfolio of investments in therapeutics, informatics and digital health that have transformational potential in healthcare and is a co-founder of Dyrnamix, a cardiovascular diagnostics and informatic biotech.
Sheryl Krevsky Elkin, PhD, is the Chief Scientific Officer at N-of-One, a QIAGEN company. An early member of the N-of-One team, Dr. Elkin has led the interpretation of thousands of patient cases, establishing a rigorous process for the analysis of scientific and clinical evidence and presentation of molecular and clinical evidence to physicians to help guide their therapeutic decisions. Dr. Elkin has taken a lead role in the development of the N-of-One clinical interpretation methodology to support clinicians in identifying therapeutic strategies specific to each patient. Prior to joining N-of-One, Dr. Elkin completed her postdoctoral fellowship at the Massachusetts Institute of Technology’s Center for Cancer Research, where she earned a fellowship from the Leukemia and Lymphoma Society. She earned her doctorate in Biological and Biomedical Sciences from Harvard Medical School and an A.B. in Biology and Music from Amherst College, graduating Phi Beta Kappa and summa cum laude, with High Distinction in Biology.
Debbie Ledet is the Vice President of Market Access with Biotheranostics, Inc. Debbie has spent the past 20 years successfully securing medical policy coverage and reimbursement for diagnostics and medical devices in start-ups and Fortune 500 companies including Cytyc/Hologic, Natera, Liposcience, Gambro and Johnson & Johnson Medical, Inc. She has held multiple Executive Leadership roles building and directing successful Market Access teams responsible for coding, coverage, contracting and reimbursement within Commercial and Governmental health plans. Debbie is an active coalition member within The Coalition for 21st Century Medicine, the American Clinical Laboratory Association (ACLA) and the California Clinical Laboratory Association (CCLA) sitting on various billing, reimbursement and public policy workgroups within these organizations. Debbie holds a Bachelor’s degree from the University of Memphis and resides in Charlotte, NC.
Dr. Arturo Loaiza-Bonilla is the current Vice Chair of Medical Oncology of Research at Cancer Treatment Centers of America – ERMC, and also Co-Founder and Chief Medical Officer at Massive Bio (www.massivebio.com). A precision oncology expert with experience at the Abramson Cancer Center of the University of Pennsylvania, University of Miami, Johns Hopkins and the National Institutes of Health, his major interest focuses in the field of innovative approaches to match oncology patients to phase 1-3 clinical and translational research cancer trials, integrating next-generation personalized molecular diagnostics, immunotherapy, biomarkers, previous therapies, and the patient’s overall status under an Artificial Intelligence-based and machine learning platform, which integrates to the electronic medical record. His company and virtual tumor board / clinical trial matching platforms have been recently featured in GenomeWeb and MedPage Today, including a first-in-the-world registry, SYNERGY-AI to match cancer patients based on Artificial Intelligence (https://clinicaltrials.gov/ct2/show/NCT03452774)
Dr. Lussier is the Associate Vice President for Information Science and Chief Knowledge Officer of the UA Arizona Health Sciences (UAHS), Founding Director of the Center for Biomedical Informatics and Biostatistics, and Professor of Medicine. He received a bachelor of engineering and his medical degree from the University of Sherbrooke, Quebec, Canada. He performed predoctoral research in the Departments of Medicine and Human Physiology at the University of Sherbrooke and then completed an internship in ophthalmology at Laval University Hospital in Quebec City, and a residency in family medicine at the University of Sherbrooke Medical Center. He was a post-doctoral residential fellow in the Department of Biomedical Informatics in the College of Surgeons & Physicians at Columbia University. Dr. Lussier’s research group conducts pioneering hypothesis-driven computational modeling predictions in precision medicine that are then validated in vitro, in vivo and in clinical trials. As a leader of the fields of translational bioinformatics and of Data Science-augmented precision medicine, he has launched successful companies and international conferences, authored 185 publications, and delivered more than 100 invited presentations in precision medicine, systems medicine, and translational bioinformatics, including 21 opening keynotes at international conferences. He has been awarded $190,000,000 in grants as principal, core leader, or co-investigator, and mentored 53 graduate and postgraduate students as well as 40 junior faculty members. Dr. Lussier’s honors include three IBM Faculty Awards, inducted Fellow of the American College of Medical Informatics (ACMI), 1st recipient of the Columbia University Faculty Mentoring Award, “Ambassador for Health Sciences” at the University of Sherbrooke (Canada), and 16 outstanding publication awards from the American Medical Informatics Association (AMIA), the International Society for Computational Biology (ISCB), and the Translational Bioinformatics Conference (TBC). In 2016, Dr. Lussier was invited among ten USA academic leaders invited by the White House for its Precision Medicine Summit, where the University of Arizona Center for Biomedical Informatics and Biostatistics that he directs has committed $20M of R&D in bringing precision medicine to practice.Prior to joining COTA, Dr. Norden served as Deputy Chief Health Officer and lead physician for oncology and genomics at IBM Watson Health. He had previously worked at Dana-Farber Cancer Institute in Boston in several capacities, including Associate Chief Medical Officer, Medical Director of Satellites and Network Affiliates, and Assistant Professor of Neuro-Oncology.
Hannah Mamuszka is the Founder and CEO of Alva10, a company focused on driving up the value of diagnostics in healthcare. Ms Mamuszka founded Alva10 after having spent almost 20 years in the Cambridge, MA biotech community, with extensive experience in both drug and diagnostic development, validation, and commercialization. Prior to founding Alva10, Ms Mamuszka was VP of Business Development at Exosome Diagnostics, where she led some of the earliest deals in the liquid biopsy diagnostic space. Earlier in her career, she was Global Director for Pharma Services at Exiqon A/S (now QIAGEN), and worked as a scientist on the NDA for Bortezmib (Velcade) at Millennium Pharmaceuticals (now Takeda).
Andrew Norden, MD, MPH, MBA, leads clinical strategy and execution at COTA. A renowned expert in real-world data and evidence and a sought after speaker and advisor on the topics, Dr.Norden is a trained neuro-oncologist, clinical researcher, and physician executive who joined COTA in 2017. Under his leadership, COTA built a scalable cancer-specific data model and approaches to clinical data curation and quality assurance that enable COTA’s provider and life sciences-facing applications. He is also responsible for COTA’s collaborative work with FDA, Friends of Cancer Research, and a number of additional partners.
David Parker, PhD, is Senior Vice President, Diagnostics Solutions at Precision for Medicine. He currently leads Precision for Medicine’s Diagnostics Solutions consulting practice and provides strategic advisory services to the firm’s diagnostics, device, and biopharma clients. David has well almost 35 years of experience in the healthcare industry, including 23 years of strategy consulting experience centered on the intersection of reimbursement, health economics, clinical science, and marketing strategy. His consulting encompasses all aspects of market access, reimbursement, evidence development strategy, and commercialization, with a particular focus on personalized medicine, advanced molecular and companion diagnostics, and targeted therapies.
John Quackenbush is Professor of Computational Biology and Bioinformatics and Chair of the Department of Biostatistics at the Harvard TH Chan School of Public Health and Professor of Biostatistics and Computational Biology at the Dana-Farber Cancer Institute. John’s PhD was in Theoretical Physics, in 1992 he received a fellowship from the National Institutes of Health to work on the Human Genome Project, which led him from the Salk Institute to Stanford University to The Institute for Genomic Research (TIGR) before moving to Harvard in 2005. John’s research uses massive data from DNA sequencing and other assays to model functional networks in human cells. By comparing networks between groups of individuals, he has found new drug targets, explored chemotherapy resistance, and investigated differences between the sexes. He has made pioneering discoveries about how the genetic variants work together to determine our traits. John has published more than 280 papers; his work has been cited more than 65,000 times. He has received numerous awards for his work, including recognition in 2013 as a White House Open Science Champion of Change. He is also the co-founder of Genospace, a precision medicine software company that was purchased by the Hospital Corporation of America in 2017.
Sumanth currently functions as the EIR within the National Account division at Anthem and Chairman of his family office, Reddy Ventures. He is on the lookout for innovators that are like minded in the healthcare space that believe empathy and patient care should come 1st followed by profit and scale. He believes the future of healthcare delivery will be de-centralized through primary care, retail clinics and small footprint infrastructure where the foundational focus is on approachable and cost effective preventative and precision medicine platforms.
Clynt Taylor is the Chief Executive Officer of Intervention Insights and a member of the company’s board of directors. He joined Insights in 2017 and brings over 20 years of experience in healthcare technology innovation, both as an entrepreneur and senior executive with startup and growing companies.
Matthew Tucker has been in healthcare for 20 years in commercial roles at startups and large multi-national companies such as Mylan, Baxter Healthcare, and Highmark Health. He has led brands and portfolios in medical devices and pharmaceuticals, as well as commercial programs such as Highmark’s Vital program. He also runs an independent consulting company helping medtech companies achieve commercial and customer success. He is the author of the book “The Selfish Career” and is on the Board of Directors of Facing Forward, a non-profit in Chicago working to end homelessness.
Debbie Windsor has 17 years in the health care landscape working with all channels within Health Care. She has worked with multiple levels of decision makers within including Hospitals, Physician Groups, Specialty Groups, IDN, Health Systems, Health Plans, and Lab Benefit Management. Debbie’s background helped her develop a deep understanding of clients and their needs and how to meet those needs with a consultative solution oriented approach. Working as Market Access Leader for five years has led her to a deep understanding of HEDIS/STAR ratings, Reimbursement and PAMA landscape, Technology, and Companion Diagnostics.
Kellie Yarnell is Vice President of Genomics Laboratories, where she leads the genomics efforts and organization. Previously, Kellie led genomic operations for Expression Analysis, an organization specializing in next-generation sequencing and bioinformatics services supporting the biopharmaceutical clinical trial and research market. Kellie brings more than 20 years of commercial expertise, scientific aptitude and strategic vision in the genomics space to the organization.
Alexandre (Sasha) Akoulitchev, MA(Oxon), PhD(UCL), FRSM
Chief Scientific Officer & Co-Founder, Oxford Biodynamics
Lori Anderson
Product Marketing Manager, XIFIN, Inc.
Ardy Arianpour, MBA
CEO & Co-Founder, Seqster
Kristine Ashcraft, MBA
CEO & Founder, YouScript
Steven D. Averbuch, MD
Precision Medicine and Oncology Rx/Dx Development, S D Averbuch Consulting, LLC
Dawn Barry, MBA
President & Co-Founder, LunaPBC
Gabriel A. Bien-Willner, MD, PhD, FCAP
Medical Director, MolDx, Chief Medical Officer, Palmetto GBA
Coco Brown
Founder, CEO, COO, Board Director and Advisor, The Athena Alliance
Trish Brown
Director; AMR Payor Partner and Field Market Access Lead, Illumina
Alessandra Cesano, MD, PhD
Chief Medical Officer, ESSA
Julie Collens, PhD
CEO Vivid Genomics
Chris Cournoyer, MA, MIT Executive Education Program
Strategic Advisor, Qiagen
Sean Downing, PhD, MBA
Director Customer Engagement, Ultivue
Nicholas Dracopoli, PhD
Chief Scientific Officer, Delfi Diagnostics, Inc.
Teresa Foy, PhD
Corporate Vice President, Head, Immuno-Oncology and Cellular Therapy, Thematic Center for Excellence, Celegene
Karen A. Garmen, EdD, MAPP, BCC
Director of Education and Engagement at Rady Children’s Institute for Genomic Medicine
Jessica Gibson, MBA
CEO & Co-Founder, Ariel Precision Medicine
Sean Glenn, PhD
Vice President of Clinical & Research Development, OmniSeq
Robert Green, MD, MPH
Associate Physician, Brigham and Women’s Hospital, Professor of Medicine, Harvard Medical School, Geneticist, Brigham and Women’s Hospital, Director, Genomes2People Research Program
Karen Gutekunst, PhD
Vice President Regulatory Affairs, Illumina
Anne-Renee Hartman, MD
Vice President of Clinical Development & Medical Affairs, GRAIL
Michael Heltzen, MBA
Chief Executive Officer and Board Member,Cardea Bio
Laura Holmes Haddad
Best Selling Author & Patient Advocate
David Houlding, MSc, CISSP, CIPP
Principal Healthcare Lead, Microsoft
Sally Howard, JD
Principal, Sally Howard Regulatory Resources
Leighton Howells
Vice President Business Development, RareCyte
Mark Kiel, MD, PhD
Founder and Chief Scientific Officer, Genomenon
Barbara Kraatz Fortini, PhD
Assistant Professor of Genetics and MSGDA Program Coordinator, School of Pharmacy and Health Sciences, Keck Graduate Institute
Tara Kochis-Stach
President, Slone Partners
Gail Marcus, MBA, MSE, PhD
Professor, Massachusetts College of Pharmacy & Health Sciences University
Marielena Mata, PhD
Director and Diagnostic Lead, Pfizer
Brian Meyer, PhD
Chairman, Department of Genetics Research Centre, KFSH&RC
Chockalingam “Palani” Palaniappan, PhD
Chief Technology Officer, Epic Sciences
John Rossi, MS
Director, Translational Medicine, Kite, A Gilead Company
Hakan Sakul, PhD
Vice President and Head of Diagnostics, Worldwide Research, Development & Medical, Pfizer
Jordi Serrats, PhD
Associate Director Neuroscience Drug Discovery Unit, External Neuroscience Innovation, Takeda
Roy Smythe, MD
Chief Executive Officer, SomaLogic
David Spetzler, MS, MBA, PhD
President and Chief Scientific Officer, Caris Life Sciences
Mary Stutts, MHA, Executive Program Graduate, Stanford University School of Business
Chief Diversity, Inclusion & Health Equity Officer at Stanford Healthcare
Tim Triche, MD, PhD
Professor, Pathology & Pediatrics, Keck School of Medicine at USC, Co-Director, Center for Personalized Medicine, Childrens’ Hospital Los Angeles
John Quackenbush, PhD
Henry Pickering Walcott Professor of Computational Biology and Bioinformatics
Chair, Department of Biostatistics, Harvard University T.H. Chan School of Public Health
Bruce Quinn, MD, PhD
Principal, Bruce Quinn Associates LLC
Christina Waters, MBA, PhD
CEO, RARE Science, Precision Medicine Council – World Economic Forum
Roseanne Welcher, PhD, MBA
Chief Scientific Officer, Agilent Technologies
Richard Williams, MBBS, PhD
Global Head of Medicine, Head of Oncology Programs ,WuXiNextCODE
Rina Wolf, MHA
VP Commercialization Strategies, Consulting and Industry Affairs XIFIN, Inc.